Chyon Yeh

Delayed-Release Oral Mesalamine at 4.8 g/day (800 mg tablet) for the Treatment of Moderately Active Ulcerative Colitis: The ASCEND II Trial

Stephen B. Hanauer, William J. Sandborn, Asher Kornbluth et al. · The American Journal of Gastroenterology · 2005 · 323 citations

Medicine, Pharmacology, Pharmacotherapy +9

Delayed-Release Oral Mesalamine 4.8 g/day (800 mg tablets) Compared with 2.4 g/day (400 mg tablets) for the Treatment of Mildly to Moderately Active Ulcerative Colitis: The ASCEND I Trial

Stephen B. Hanauer, William J. Sandborn, Christian Dallaire et al. · Canadian Journal of Gastroenterology · 2007 · 164 citations · Full text

Pharmacy, Pharmacotherapy, Clinical Pharmacology +14

Endovascular repair for blunt thoracic aortic injury using the Zenith Alpha low-profile device

Benjamin W. Starnes, Amit J. Dwivedi, Joseph S. Giglia et al. · Journal of Vascular Surgery · 2015 · 22 citations

Medicine, Emergency Medicine, Surgery +16

Updated outcomes from the TRANSFIX study to evaluate endovascular repair of blunt thoracic aortic injuries with the Zenith Alpha thoracic device

Benjamin W. Starnes, Amit J. Dwivedi, Joseph S. Giglia et al. · Journal of Vascular Surgery · 2020 · 18 citations · Full text

Medicine, Surgery, Cardiothoracic Surgery +15

Two-year target vessel-related outcomes following use of off-the-shelf branched endografts for the treatment of thoracoabdominal aortic aneurysms

Nikolaos Tsilimparis, Michel Bosiers, Timothy Resch et al. · Journal of Vascular Surgery · 2023 · 13 citations · Full text

Medicine, Surgery, Cardiothoracic Surgery +14